The largest-ever assessment of cancer risk following initiation of TNF inhibitor therapy in patients with spondyloarthritis (SpA) found no increased cancer risk among these patients. The relative risk of cancer for patients with SpA not being treated with anti-TNF therapy was 1.1 compared with the general population and 0.8 for those on anti-TNF therapy compared with TNFi-naïve patients.

Click here for more.